Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett’s Esophagus in a Rat Model

Digestive Diseases and Sciences

Volumn 60, Issue 9, 2015, Pages 2654-2661

  Kohata, Yukie ^a   Nakahara, Kenichi ^a   Tanigawa, Tetsuya ^a   Yamagami, Hirokazu ^a   Shiba, Masatsugu ^a   Watanabe, Toshio ^a   Tominaga, Kazunari ^a   Fujiwara, Yasuhiro ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Barrett s esophagus; Esophageal microbiome; Rebamipide; Terminal restriction fragment length polymorphism

Indexed keywords

DNA 16S; REBAMIPIDE; ALANINE; ANTIULCER AGENT; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CLOSTRIDIUM; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFECT; ENTEROCOCCUS; ESOPHAGOJEJUNOSTOMY; GENE EXPRESSION; HISTOPATHOLOGY; LACTOBACILLUS; MALE; MICROBIOME; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STREPTOCOCCUS; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ESOPHAGUS; GENETICS; MICROBIOLOGY; MICROFLORA; WISTAR RAT;

ALANINE; ANIMALS; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CLOSTRIDIUM; DISEASE MODELS, ANIMAL; ENTEROCOCCUS; ESOPHAGUS; LACTOBACILLUS; MALE; MICROBIOTA; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; QUINOLONES; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; STREPTOCOCCUS;

EID: 84939564409     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3662-4     Document Type: Article

References (30)

1. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia–dysplasia–adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:965–973.
2. Pera M. Experimental Barrett’s esophagus and the origin of intestinal metaplasia. Chest Surg Clin N Am. 2002;12:25–37.
3. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci. 2002;115:1783–1789.
4. Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus. 2008;21:43–50.
5. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451–459.
6. Moons LM, Kusters JG, Bultman E, et al. Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207:269–276.
7. Dvorakova K, Payne CM, Ramsey L, et al. Increased expression and secretion of interleukin-6 in patients with Barrett’s esophagus. Clin Cancer Res. 2004;10:2020–2028.
8. Kohata Y, Fujiwara Y, Machida H, et al. Role of Th2 cytokines in the development of Barrett’s esophagus in rats. J Gastroenterol. 2011;46:883–893.
9. Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol. 2013;19:1541–1550.
10. Yang L, Chaudhary N, Baghdadi J, Pei Z. Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J. 2014;20:207–210.
11. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137:588–597.
12. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3–S11.
13. Tanigawa T, Watanabe T, Otani K, Nadatani Y, et al. Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha-defensin 5. Eur J Pharmacol. 2013;704:64–69.
14. Pera M, Brito MJ, Poulsom R, et al. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis. 2000;21:1587–1591.
15. Levrat M, Lambert R, Kirshbaum G. Esophagitis produced by reflux of duodenal contents in rats. Am J Dig Dis. 1962;7:564–573.
16. Pera M, Cardesa A, Bombi JA, Ernst H, Pera C, Mohr U. Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague–Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine. Cancer Res. 1989;49:6803–6808.
17. Imaeda H, Fujimoto T, Takahashi K, Kasumi E, Fujiyama Y, Andoh A. Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipide-treated mice. Digestion. 2012;86:250–257.
18. Nagashima K, Hisada T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol. 2003;69:1251–1262.
19. Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing. PLoS One. 2014;9:e105592.
20. Muyzer G, de Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol. 1993;59:695–700.
21. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70:6459–6465.
22. Songjinda P, Nakayama J, Tateyama A, et al. Differences in developing intestinal microbiota between allergic and non-allergic infants: a pilot study in Japan. Biosci Biotechnol Biochem. 2007;71:2338–2342.
23. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol. 2007;73:32–39.
24. Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther. 2013;37:1084–1092.
25. Kauppila JH, Selander KS. Toll-like receptors in esophageal cancer. Front Immunol. 2014;7:200.
26. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012;18:2138–2144.
27. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut. 2008;57:181–187.
28. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506–G513.
29. Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012;208:269–280.
30. Lind A, Koenderman L, Kusters JG, Siersema PD. Squamous tissue lymphocytes in the esophagus of controls and patients with reflux esophagitis and Barrett’s esophagus are characterized by a non-inflammatory phenotype. PLoS One. 2014;9:e106261.